Halozyme intends to expand its drug discovery and development portfolio through the acquisition of Evotec. Halozyme intends to acquire all shares of Evotec at a price of €11 per share. “The combination of Halozyme and Evotec would diversify and extend Halozyme revenue and EBITDA growth and durability well into the next decade and beyond,” said Helen Torley, president and CEO of Halozyme.

Evotec has confirmed receipt of the “no-contact offer to the shareholders of the company” and intends to carefully analyze the “expression of interest”, decide on further steps and further inform the capital markets in accordance with legal requirements.

According to Morgan Stanley, a takeover battle for Evotec could emerge after it became known that the financial investor Triton increased its stake in the company from 5.6% to around 9.2% last week. According to a notification to the US Securities and Exchange Commission (SEC), this figure has now risen to 9.99%. Bloomberg had reported that Triton was sounding out a takeover and had sought talks with Evotec's management board. A spokesperson for the company subsequently said that there had been no discussion or negotiations beyond Triton's entry.

Halozyme generated sales of around $830 million in the last financial year 2023, more than half of which came from licenses. The company has licensed its Enhanze drug delivery technology to pharmaceutical and biotech companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb and Chugai and has two proprietary commercial products, Hylenex and Xyosted, commercial partnered products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.